HSE approves Skyclarys reimbursement for Friedreich's ataxia
Analysis based on 23 articles · First reported Aug 14, 2026 · Last updated Aug 25, 2026
The approval is positive for Biogen, securing a new market for Skyclarys and potentially boosting revenues, though the discounted price may pressure margins. For Republic of Ireland, the decision increases public health spending but addresses a significant unmet need, with limited direct impact on broader markets.
The Republic of Ireland — Health Service Executive (HSE) has approved reimbursement for Skyclarys (omaveloxolone), the first treatment for Friedreich's ataxia, a rare progressive neuromuscular disease affecting about 200 people in Republic of Ireland. The decision, made by the HSE's Senior Management Team on August 25, 2026, followed a substantially improved financial offer from manufacturer Biogen after intensive negotiations. This reversed an earlier recommendation by the HSE Drugs Group, which had cited high cost and limited efficacy evidence. The approval ends a long-running campaign by patients and families, who had protested and lobbied for access. Taoiseach Micheál Martin welcomed the decision, and the Government will support its implementation. Skyclarys is already approved in the US and EU, and is publicly funded in several European countries. The drug costs about €280,000 per patient annually, with potential state costs estimated at €130 million over five years, though the improved offer reduced this burden.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard